[
  {
    "ts": null,
    "headline": "Morgan Stanley Ups the Ante on These 2 Life Science Tool Stocks",
    "summary": "The broad healthcare sector accounts for roughly one-fifth of the U.S. economy and continues to expand. While most attention tends to go to the direct-care segment, the life-sciences industry is an equally critical pillar of the system. It spans everything from laboratory services to drug discovery, and its research and development efforts are major drivers of progress in patient care. Grand View Research estimated the life sciences market at $167.82 billion worldwide in 2004, and expects it to",
    "url": "https://finnhub.io/api/news?id=0d8a52cb2bc1ef06d60edc040e46ae496c2fab7cacac0081318596b032750d51",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764932993,
      "headline": "Morgan Stanley Ups the Ante on These 2 Life Science Tool Stocks",
      "id": 137697219,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "The broad healthcare sector accounts for roughly one-fifth of the U.S. economy and continues to expand. While most attention tends to go to the direct-care segment, the life-sciences industry is an equally critical pillar of the system. It spans everything from laboratory services to drug discovery, and its research and development efforts are major drivers of progress in patient care. Grand View Research estimated the life sciences market at $167.82 billion worldwide in 2004, and expects it to",
      "url": "https://finnhub.io/api/news?id=0d8a52cb2bc1ef06d60edc040e46ae496c2fab7cacac0081318596b032750d51"
    }
  },
  {
    "ts": null,
    "headline": "How New Signals Are Gradually Shifting the Narrative for Danaher",
    "summary": "Danaher’s valuation narrative has been nudged higher, with the fair value estimate edging up to about $255.67 from roughly $254.20 as analysts refine their long term growth and risk assumptions. While the discount rate has ticked up to around 8.00% and revenue growth expectations have slipped only marginally to nearly 5.47%, the Street’s tone has shifted to a more balanced, wait and see stance amid slower near term recovery in key end markets. Stay tuned to see how to track these subtle yet...",
    "url": "https://finnhub.io/api/news?id=f82ddd0e1136db99ac6796bd42d8c3fc53f2f7908d02f44bd1df826cb90ee8b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764925782,
      "headline": "How New Signals Are Gradually Shifting the Narrative for Danaher",
      "id": 137697220,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "Danaher’s valuation narrative has been nudged higher, with the fair value estimate edging up to about $255.67 from roughly $254.20 as analysts refine their long term growth and risk assumptions. While the discount rate has ticked up to around 8.00% and revenue growth expectations have slipped only marginally to nearly 5.47%, the Street’s tone has shifted to a more balanced, wait and see stance amid slower near term recovery in key end markets. Stay tuned to see how to track these subtle yet...",
      "url": "https://finnhub.io/api/news?id=f82ddd0e1136db99ac6796bd42d8c3fc53f2f7908d02f44bd1df826cb90ee8b4"
    }
  }
]